Gilead Sciences has named Deborah Telman EVP of corporate affairs and general counsel. Telman, who will report directly to CEO Daniel O’Day, succeeds Brett Pletcher, who is retiring after 17 years with the company.
“Deb is a highly accomplished and experienced leader,” O’Day said in a statement. “With more than 25 years’ experience of building and leading global teams, a strong focus on culture and a passion for health equity, I know that Deb will be an outstanding addition to our team.”
Telman joins Gilead from Organon, where she served as general counsel. Gilead recently tapped Stacey Ma, PhD, as EVP, pharmaceutical development and manufacturing.
